1. Home
  2. List
Reference Patent

Reference - List

  • 155 Hits
  • Search Condition : Filter (MeSH = Protein Kinase Inhibitors / pharmacology*)
Species Resource Title
Human and Animal Cells Hep G2(RCB1648) Polarity directed optimization of phytochemical and in vitro biological potential of an indigenous folklore: Quercus dilatata Lindl. ex Royle.
Human and Animal Cells YSCCC(RCB1549) , HuCCT1(RCB1960) , RBE(RCB1292) , SSP-25(RCB1292) Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Human and Animal Cells KP4(RCB1005) LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Human and Animal Cells MKN45(RCB1001) Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.
Human and Animal Cells COLO-320(RCB1193) , LoVo(RCB1639) Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
Human and Animal Cells ME-180(RCB2160) , Ca Ski(RCB1947) Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
Human and Animal Cells II-18(RCB2093) Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Human and Animal Cells HS-Sch-2(RCB2230) , HS-PSS(RCB2362) , YST-1(RCB2136) Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Human and Animal Cells Ba/F3(RCB0805) Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells.
Human and Animal Cells iPS-MEF-Ng-20D-17(APS0001) The efficacy of PI3Kγ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells.
Human and Animal Cells K562 Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Human and Animal Cells HeLa CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity.
Human and Animal Cells 8505C(RCB2103) , HTC/C3(RCB0452) , HOTHC(RCB0662) BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.
Human and Animal Cells 293T(RCB2202) Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Human and Animal Cells WI-38(RCB0702) Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Human and Animal Cells Li-7(RCB1941) Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
Human and Animal Cells NUGC-4(RCB1939) The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
Human and Animal Cells HuH-28(RCB1943) , TGBC1TKB(RCB1129) , TGBC24TKB(RCB1196) Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets.
Human and Animal Cells JLS-V9(RCB2651) Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model.
Human and Animal Cells PC-9(RCB4455) Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.